Clinical trial NCT00006374 (phase 2, status: withdrawn)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cisplatin, etoposide, paclitaxel, topotecan hydrochloride
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Diagnosis of extensive stage small cell lung cancer At least 1
        bidimensionally measurable non CNS lesion At least 1 cm in one diameter and at least 2 cm
        in another diameter by CT or MRI scan At least 2 cm in two diameters by x-ray, ultrasound,
        or for palpable tumor masses by physical exam Measurable skin lesion at least 1 cm in at
        least one diameter by photography No symptomatic CNS and/or leptomeningeal metastases
        requiring corticosteroid therapy to control symptoms

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
        least 3 months Hematopoietic: WBC at least 3,500/mm3 Hemoglobin at least 9.0 g/dL
        Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin
        no greater than 2.0 mg/dL SGOT, SGPT, and alkaline phosphatase no greater than 2 times
        upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present)
        Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min
        Cardiovascular: No preexisting cardiac disease No congestive heart failure No cardiac
        arrhythmia requiring therapy No myocardial infarction within the past 3 months Other: Not
        pregnant or nursing Negative pregnancy test Fertile patients must use effective
        contraception for 3 months before, during, and for at least 4 weeks after study No active
        uncontrolled infection No other concurrent or prior malignancies within the past 5 years
        except adequately treated basal or squamous cell skin cancer, carcinoma in situ of the
        cervix, or stage I low grade prostate cancer No other severe medical problem or any other
        medical condition that would preclude study

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: See Disease Characteristics Radiotherapy: At least 24 hours
        since prior radiotherapy if no marked bone marrow suppression expected At least 6 weeks
        since prior radiotherapy to measurable lesion if evidence of progression Concurrent
        radiotherapy for bone pain control allowed Surgery: At least 3 weeks since prior surgery
        Other: At least 30 days or 5 half lives (whichever is longer) since prior investigational
        drug No other concurrent investigational drugs